KALA BIO (NASDAQ:KALA) Posts Earnings Results, Beats Estimates By $0.50 EPS

KALA BIO (NASDAQ:KALA) posted its quarterly earnings data on Tuesday. The company reported ($1.93) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.43) by $0.50, Zacks reports.

KALA BIO Trading Down 4.1 %

NASDAQ:KALA traded down $0.29 on Wednesday, reaching $6.80. The stock had a trading volume of 31,414 shares, compared to its average volume of 84,371. The company has a market cap of $31.35 million, a price-to-earnings ratio of -0.55 and a beta of -2.13. KALA BIO has a 12-month low of $4.21 and a 12-month high of $10.97. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.07 and a quick ratio of 3.07. The firm’s fifty day moving average is $5.97 and its two-hundred day moving average is $6.29.

Wall Street Analyst Weigh In

Separately, Oppenheimer reissued an “outperform” rating and set a $15.00 price target on shares of KALA BIO in a research note on Monday, August 19th.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.